Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced Cancer

PURPOSE: To define the maximum tolerated dose (MTD), toxicities, and pharmacokinetics of 17-allylamino-17-demethoxygeldanamycin (17-AAG) when administered using continuous and intermittent dosing schedules. EXPERIMENTAL DESIGN: Patients with progressive solid tumor malignancies were treated with 17-...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Solit, David B., Ivy, S. Percy, Kopil, Catherine, Sikorski, Rachel, Morris, Michael J., Slovin, Susan F., Kelly, W. Kevin, DeLaCruz, Anthony, Curley, Tracy, Heller, Glenn, Larson, Steven, Schwartz, Lawrence, Egorin, Merrill J., Rosen, Neal, Scher, Howard I.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2007
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3203693/
https://ncbi.nlm.nih.gov/pubmed/17363532
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-06-1863
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky